(Sharecast News) - RUA Life Sciences reported a sharp increase in revenue for the 18 months ended 30 September on Tuesday, reflecting its successful transition from a research-led organisation to a revenue-generating medical device group.

The AIM-traded company, which develops and commercialises implantable polymer technologies under the Elast-Eon brand, said...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE